<DOC>
	<DOCNO>NCT01458561</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , control investigation . Subjects bleed expose parenchymal surface observe intraoperatively follow ligature vessel visible unaided eye randomize adjunctive application BioFoam standard topical hemostatic agent ( Gelfoam thrombin , form Gelfoam Plus ) entire expose parenchymal surface . Following primary treatment expose parenchymal surface prescribe randomization scheme , treatment site visually evaluate continued presence bleeding . The overall objective investigation collect clinical data concern safety effectiveness BioFoam use adjunct conservative measure achieve hemostasis , manual pressure , cautery , ligation , intraoperative capillary , arteriolar , venular bleeding ( 5 second stack 5 gauze surface `` Bleeding Score '' = 1b 2 , score validate ) newly resect liver parenchyma hemodynamically stable ( American College Surgeons ' Advanced Trauma Life Support Class I Hemorrhage ) non-coagulopathic patient open treatment expose liver parenchyma versus standard topical hemostatic agent , Gelfoam Plus . It intend traumatic liver injury . The investigation conduct maximum three investigational site .</brief_summary>
	<brief_title>Adjunctive Application BioFoam Surgical Matrix Liver Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Gelatin Sponge , Absorbable</mesh_term>
	<criteria>Preoperative Subject undergo elective liver resection procedure require treatment expose parenchymal surface due intraoperative presence blood follow ligature vessel visible unaided eye ; Subject adequate hepatic function indicate Model EndStage Liver Disease ( MELD ) score &lt; 10 ≤30 day ≤7 day prior surgery ; Subject adequate hemostatic function identify international normalized ratio ( INR ) , platelet count , activate clotting time within central laboratory 's normal reference range ; Subject authorize legal representative willing able give prior write informed consent investigation participation ; Subject ≥ 18 year age . Preoperative Subject know suspected sensitivity product bovine origin Subject know suspected sensitivity glutaraldehyde Subject active infection ( either systemic treatment region ) hepatic cyst due parasitic disease and/or abscess due bacterial and/or amebic disease ; Subject abnormal calcium metabolism identify value ionized calcium serum calcium correct serum albumin outside central laboratory 's normal reference range ; Subject abnormal renal status identify estimate glomerular filtration rate ( eGFR ) , blood urea nitrogen ( BUN ) , serum creatinine , sodium , chloride , potassium , and/or bicarbonate value outside central laboratory 's normal reference range ; Subject hyperparathyroidism identify intact parathyroid hormone level &gt; 72 pg/mL , serum calcium &gt; 10.6 mg/dL , phosphate &lt; 2.4 mg/dL , , secondary tertiary hyperparathyroidism , alkaline phosphatase &gt; 147 U/L Subject pancreatic amylase and/or lipase value outside central laboratory 's normal reference range ; Subject blunt and/or penetrate liver trauma ; Subject diagnose coagulation disorder ; Subject whose lifeexpectancy le required prescribed followup duration ; Subject treat investigational product complete entire followup period investigational product ; Subject surgical implant would interfere necessary followup imaging ; Subject pregnant ( confirm urine pregnancy test ) , plan become pregnant followup period , actively breastfeed ; Subject undergoing concomitant procedure ( 1 ) cholecystectomy , ( 2 ) umbilical hernia repair , ( 3 ) uncomplicated colon resection ( i.e. , significant spillage ) ; Subject immunocompromised ; Subject American Society Anesthesiologist ( ASA ) Score &gt; 2 Subject MELD score ≥10 ≤30 day ≤7 day prior surgery ; Subject diagnose autoimmune disease ; Subject surgeon intend use adhesion prevention product . Subject return operating room ( OR ) address complication associate liver resection , include limited hematoma evacuation biliary leak . Intraoperative Inclusion Criterion : Subject bleeding ( assignment `` Bleeding Score '' 1 2 ) expose parenchymal surface ligature vessel visible unaided eye removal clamp use hemostasis observe Intraoperative Exclusion Criterion : Subject major intraoperative bleeding incidence resection procedure occur ( i.e. , subject assignment American College Surgeons Advanced Trauma Life Support Hemorrhage Class II , III , IV Hemorrhage )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hemostatic agent</keyword>
	<keyword>Liver surgery</keyword>
	<keyword>Hemostasis</keyword>
</DOC>